2024
Fetal behavior and gestational serotonin reuptake inhibitor exposure: relationships between behavior, drug dosage, plasma drug level, and a measure of drug bioeffect
Salisbury A, Anderson G, Yang A, Stika C, Rasmussen-Torvik L, Gollan J, Wisner K. Fetal behavior and gestational serotonin reuptake inhibitor exposure: relationships between behavior, drug dosage, plasma drug level, and a measure of drug bioeffect. Neuropsychopharmacology 2024, 49: 1968-1977. PMID: 39127823, PMCID: PMC11480508, DOI: 10.1038/s41386-024-01923-1.Peer-Reviewed Original ResearchConceptsPlatelet 5-HT levelsSerotonin reuptake inhibitorsPlasma drug concentrationsDEP groupPresence of maternal depressionSerotonin reuptake inhibitor exposureDrug exposureSRI groupDrug dosageMeasure of drug exposureDrug concentrationsPlasma drug levelsMother-infant pairsGroups of mother-infant pairsReuptake inhibitorsMaternal depressionFetal behaviorCord bloodFetal movementsPlatelet serotoninDrug levelsInhibitor exposureDepressionSerotoninCordPhase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC).
Sehgal K, Shi R, Pappa T, Min J, Oakley L, ONeill A, Dennis M, Deshpande H, Haddad R, Lorch J. Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC). Journal Of Clinical Oncology 2024, 42: 6109-6109. DOI: 10.1200/jco.2024.42.16_suppl.6109.Peer-Reviewed Original ResearchMetastatic medullary thyroid carcinomaTreatment-related adverse eventsProgression-free survivalRAIR-DTCProgression-FreeOverall survivalClinical trialsMedian progression-free survivalCycle 2 onwardsMedian overall survivalPhase II clinical trialMedullary thyroid carcinomaPhase II trialMulti-kinase inhibitorII clinical trialsSimon's two-stage designRECIST v1.1Systemic therapyTolerated doseStage 2Thyroid carcinomaMedian agePlanned escalationTherapeutic optionsInhibitor exposure
2023
Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor–Induced Hypophysitis
Quandt Z, Kim S, Villanueva-Meyer J, Coupe C, Young A, Kang J, Yazdany J, Schmajuk G, Rush S, Ziv E, Perdigoto A, Herold K, Lechner M, Su M, Tyrrell J, Bluestone J, Anderson M, Masharani U. Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor–Induced Hypophysitis. Journal Of The Endocrine Society 2023, 7: bvad012. PMID: 36860908, PMCID: PMC9969737, DOI: 10.1210/jendso/bvad012.Peer-Reviewed Original ResearchPD-1/PD-L1 inhibitor monotherapyImmune-related adverse eventsPD-L1 inhibitor monotherapyMagnetic resonance imagingCheckpoint inhibitorsInhibitor monotherapyHLA typesPD-1/PD-L1 inhibitorsCTLA-4/PDCTLA-4 inhibitorsImmune checkpoint inhibitorsPD-L1 inhibitorsThyroid function testsInhibitor combination therapyTiming of onsetAdverse eventsMRI changesClinical presentationFunction testsImaging findingsCombination therapyMean ageInhibitor exposureEffect modificationHLA typing
2022
The Association Between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients With Cirrhosis: A Veterans Affairs Cohort Study
Mahmud N, Serper M, Taddei TH, Kaplan DE. The Association Between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients With Cirrhosis: A Veterans Affairs Cohort Study. Gastroenterology 2022, 163: 257-269.e6. PMID: 35398042, PMCID: PMC10020994, DOI: 10.1053/j.gastro.2022.03.052.Peer-Reviewed Original ResearchConceptsLiver-related mortalityPPI exposureGastrointestinal bleedingCause mortalityProton pump inhibitor exposurePrior gastrointestinal bleedingTime-updated variablesCause-specific mortality analysesLarge national cohortVeterans Health AdministrationRisk of infectionCardiovascular comorbiditiesPPI useCohort studyStatin exposureCox regressionRetrospective studyAdverse outcomesAppropriate indicationsNational cohortInhibitor exposureSevere infectionsCirrhosis diagnosisAdditional adjustmentAdjusted model
2021
Neuroinflammation Associated With Tumor Necrosis Factor-α Inhibitor Exposure
Yu AW, Pecsok M, Longbrake EE, Wesley SF. Neuroinflammation Associated With Tumor Necrosis Factor-α Inhibitor Exposure. Neurology Clinical Practice 2021, 11: e488-e496. PMID: 34484946, PMCID: PMC8382406, DOI: 10.1212/cpj.0000000000001014.Peer-Reviewed Original ResearchMRI findingsBrain MRIYale New Haven Health SystemNonspecific MRI findingsRetrospective cohort studyCommon abnormal findingDetailed chart reviewRisk stratification parametersElectronic medical recordsAdditional immunotherapyNeuroinflammatory phenomenaTNFi discontinuationTNFi exposureChart reviewCohort studyAbnormal findingsPeriod prevalenceT2 hyperintensityAutoimmune diseasesClinical spectrumInhibitor exposureMedical recordsTumor necrosisTNFiNeuroinflammation
2018
Modulations in extracellular calcium lead to H+-ATPase-dependent acid secretion: a clarification of PPI failure
Kitay AM, Schneebacher MT, Schmitt A, Heschl K, Kopic S, Alfadda T, Alsaihati A, Link A, Geibel J. Modulations in extracellular calcium lead to H+-ATPase-dependent acid secretion: a clarification of PPI failure. AJP Gastrointestinal And Liver Physiology 2018, 315: g36-g42. PMID: 29517927, DOI: 10.1152/ajpgi.00132.2017.Peer-Reviewed Original ResearchConceptsAcid secretionParietal cellsExtracellular calciumGastric parietal cellsProton pump inhibitor exposureExtracellular CaPotassium-free conditionsRecurrent reflux symptomsCalcium sensing receptorGastric acid secretionPPI failurePPI therapyReflux symptomsIsolated gastric glandsInhibitor exposureCalcimimetic R568Pharmacological targetsSensing receptorAbsence of sodiumCalcium concentrationCaSRGastric glandsSecretionATPase activityExcretion pathway
2015
Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative
Tarlock K, Hansen M, Hylkema T, Ries R, Farrar J, Auvil J, Gerhard D, Smith M, Davidsen T, Gesuwan P, Hermida L, Marra M, Mungall A, Mungall K, Ma Y, Zong S, Long W, Boggon T, Alonzo T, Kolb E, Gamis A, Meshinchi S. Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative. Blood 2015, 126: 87. DOI: 10.1182/blood.v126.23.87.87.Peer-Reviewed Original ResearchFLT3/ITDChildren's Oncology GroupFLT3 mutationsOncology GroupPediatric cohortPediatric AMLFLT3 geneActivating mutationsTyrosine kinase domainAcute myeloid leukemiaDe novo resistanceInternal tandem duplicationJuxtamembrane domainCommon activating mutationsCo-occurring mutationsTargeted exome captureResistance conferring mutationsCOG trialsChildhood AMLUnnecessary toxicityInhibitor exposureFLT3 inhibitionNovo resistanceAdult studiesExcessive activation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply